COLORADO SPRINGS — The Lynn Health Science Institute in Colorado Springs announced Wednesday that they were awarded the Moderna Phase 3 COVID-19 vaccine study.
The press release sent by the Lynn Health Science Institute (LHSI) said that the study slated to start this month is a 24-month long study for healthy individuals age 18 and above. They are looking for 300 people to participate.
The institute stated that Dr. Ripley Hollister, who has served the Colorado Springs community for over 20 years, would serve as the Principal Investigator for the study.
“I’m hoping we do something that is good for humanity,” Dr. Hollister said.
They stated that the study would determine if participants receiving the potential vaccine develop antibodies that contribute to virus resistance for COVID-19.
Are you interested in participating? You must meet the inclusion and exclusion criteria that have been established by Moderna, Inc.’s clinical trial protocol. The data from this trial could lead to the development of the first vaccine for COVID-19, according to the LHSI.
Some things participants need to have to qualify:
- 18 years or older
“To be in the study it takes a certain type of person and a certain type of mindset,” Dr. Hollister said.
It will be a two-year-long study. Those who are picked to participate will have to keep a journal throughout the study meet with Dr. Hollister at least seven times, receive two doses of the vaccine 28 days apart. He said those who are involved would be compensated.
When coming into the office for the visits with Dr. Hollister, he stated that safety measures will be in place for the patient like handwashing, facemasks, and other safety precautions. They will also be offering Telehealth visits throughout the study.
“This vaccine doesn’t induce infection; it induces an immune response within the system. There is no virus in this vaccine,” Dr. Hollister said.
People wanting to participate who have been diagnosed with active COVID-19 or those who have recovered from the COVID-19 infection are not eligible to participate in the study.
Throughout the study, qualified participants will receive two vaccinations and be monitored for the remainder of the study.
Interested individuals may visit their website or contact the Lynn call center 719-224-9044.